Quick context
LL-37
属于先天免疫系统；研究涉及抗微生物、炎症及创伤修复信号。
No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.
Back to all 64 profiles
Community/research information only未获 FDA/EMA 批准
Community protocol · LL-37
LL-37: community information and evidence, clearly separated.
A complete substance profile covering documented community themes, scientific context and explicit safety boundaries. Missing or non-standardised data are not replaced with estimates.
Also known as: LL37 · Human cathelicidin
Sources checked: 27 August 2026
重要安全与责任声明
本页记录并评估网络社区信息，不构成医疗或治疗建议、个体咨询，也不是使用邀请。
No medical, therapeutic or individual recommendation. Information is provided without warranty and used at your own risk. No liability for calculation errors, use, contamination, interactions or consequences.
Amounts, timing and cycles
Community/research information only
No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.
Amount status
Different amounts circulate online; no regulator-confirmed safe or effective dose exists.
Profile evidence level: preclinical.
Timing
Community claims about time of day, fasting windows or training intervals are not validated clinical standards.
No individual recommendation.
Cycle/duration
Cycles and breaks are community constructs and do not prevent adverse effects or unknown long-term consequences.
No individual recommendation.
External community reference available
The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.
Open community source复配与 U-100 换算
复配计算器
For clearly identified single lyophilised substances, the calculator only shows the arithmetic between vial amount, liquid volume and target amount. It does not check identity, purity, sterility, solubility, stability or solvent suitability. The entered target is not a recommendation.
复配计算器
Calculates concentration, volume and theoretical U-100 units. The preloaded 200 µg is only the reference page's arithmetic example.
Concentration
3,333.33 µg/ml
Calculated volume
0.06 ml
U-100 units
6 U
Calculated portions per vial
50
Calculation aid, not dosage or use advice. Incorrect inputs, a different syringe scale, measurement error, dead space or unknown vial content produce incorrect results.
Mechanism and research questions
Endogenous antimicrobial host-defence peptide
LL-37 is classified as “Endogenous antimicrobial host-defence peptide”. 属于先天免疫系统；研究涉及抗微生物、炎症及创伤修复信号。 This describes the investigated pathway but does not validate a community use, amount, route or combination.
抗菌宿主防御
研究人员研究天然存在的防御肽如何攻击细菌并影响炎症信号,类似于皮肤和黏膜的第一道防线。在实验室中测量细菌生长和免疫标志物。
免疫调节肽
这项研究考察某肽如何调节免疫细胞活性,类似于增强或抑制免疫反应的旋钮。研究中测量免疫细胞计数和炎症标志物。
细胞迁移肽
这项研究考察某肽如何影响细胞向损伤部位的迁移,类似于工人们赶往施工现场。在实验室模型中测量细胞迁移的速度和程度。
What communities discuss
These themes describe discussion and vendor claims. They do not prove benefit, safety, product identity or suitable use.
肠道健康轶事
人们报告在使用胃保护或免疫调节肽后主观感受到的消化改善,通常没有客观诊断依据。这类自我观察无法证明对肠道的确切效果。
伤口愈合轶事
人们报告在使用某些肽后感觉伤口或肌腱问题愈合更快,通常没有对照组或客观测量。这类个人经历并不能证明实际的疗效或安全性。
来源与纯度讨论
人们讨论哪些商家被认为更值得信赖,以及不同批次之间纯度检测结果的差异。这类社区评估基于有限的样本,无法替代对每一批次进行的独立实验室检测。
Adverse effects and risk boundaries
- 调节免疫或抗菌信号可能影响炎症、超敏反应、感染风险及不可预测的免疫反应；给药途径和制剂至关重要。
- Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
- A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.
Exclusion groups and professional assessment
- 自身免疫病、移植、免疫抑制、活动性感染、癌症和妊娠均需专科评估。
- Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
- Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.
Monitoring and laboratory markers
- 根据适应证，血常规、炎症指标、感染征象、肝肾功能及免疫参数可能相关；不存在通用社区监测方案。
- Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.
Evidence boundary
临床前
抗菌和抗炎作用仍在研究中,尚无确认的临床用途。
Published evidence
现有数据主要来自动物或细胞模型;缺乏可靠的人体有效性和安全性数据。
LL-37属于先天免疫防御,这使其有别于胸腺素α1等发挥适应性作用的免疫肽。
Storage and stability
- The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
- Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
- Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.
Troubleshooting and error sources
- U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
- Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
- Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
- Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.
Regulatory status and WADA
未获 FDA/EMA 批准
没有 FDA 或 EMA 批准的药品；有效性与安全性尚未确立。
WADA 2026
The atlas has no explicit WADA flag for this profile. That does not automatically mean every form, route or related class is permitted in sport.
WADA — 2026 Prohibited ListComparisons and related profiles
Combinations / stacks
- Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
- Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
- Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.
Frequently asked questions
Is an amount shown here a recommendation?
No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.
Does the U-100 calculator prove correct use?
No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.
Can this profile be combined with other substances?
Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.
Which source controls when information conflicts?
For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.
Are community claims clinical evidence?
No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.
Sources and evidence layers
Primary sources and official registries take priority. The community reference is labelled separately.
- Primary/technical sourceFDA warning letter: listed peptide substances
- Community referenceLL-37 — Peptide Dosing Protocols